Background: Alzheimer’s disease (AD) presents with an earlier onset age and increased symptom severity in African Americans and Hispanics.
Objective: Although the prevalence of plaques and tangles may not exhibit ethnicity-related differences, levels of neurodegenerative proteins have not been described.
Methods: Here, levels of five proteins (i.e., S100B, sRAGE, GDNF, Aβ40, and Aβ42) and the Aβ42/Aβ40 ratio were measured in postmortem samples of the middle temporal gyrus (BA21) from age-matched African Americans and Caucasians with AD (n = 6/gender/ethnicity).
Results: S100B levels were increased 17% in African Americans (p < 0.003) while sRAGE was mildly decreased (p < 0.09). Aβ42 levels were increased 121% in African Americans (p < 0.02), leading to a 493% increase in the Aβ42/Aβ40 ratio (p < 0.002). Analysis of GDNF levels did not indicate any significant effects. There were no significant effects of gender and no significant ethnicity with gender interactions on any analyte. Effect size calculations indicated “medium” to “very large” effects.
Conclusion: S100B is typically elevated in AD cases; however, the increased levels in African Americans here may be indicative of increased severity in specific populations. Increased Aβ42/Aβ40 ratios in the current study are compatible with increased disease severity and might indicate increased AD pathogenesis in African Americans. Overall, these results are compatible with a hypothesis of increased neuroinflammation in African Americans with AD.
ManlyJJ, MayeuxR (2004) Ethnic differences in dementia and Alzheimer’s disease. In Critical Perspectives on Racial and Ethnic Differences in Health in Late LifeAndersonNA, BulataoRA, CohenB, eds. National Academy Press, pp. 95–142.
2.
DemirovicJ, PrineasR, LoewensteinD, BeanJ, DuaraR, SevushS, SzapocznikJ (2003) Prevalence of dementia in three ethnic groups: The South Florida program on aging and health. Ann Epidemiol13, 472–478.
3.
Alzheimer’s Association (2014) 2014 Alzheimer’s disease facts and figures. Alzheimers Dement10, e47–92.
4.
TangMX, CrossP, AndrewsH, JacobsDM, SmallS, BellK, MerchantC, LantiguaR, CostaR, SternY, MayeuxR (2001) Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology56, 49–56.
5.
TaylorDHJr, SloanFA, DoraiswamyPM (2004) Marked increase in Alzheimer’s disease identified in medicare claims records between 1991 and 1999. J Gerontol A Biol Sci Med Sci59, 762–766.
6.
SteenlandK, GoldsteinFC, LeveyA, WhartonW (2015) A meta-analysis of Alzheimer’s disease incidence and prevalence comparing African-Americans and Caucasians. J Alzheimers Dis50, 71–76.
7.
MehtaKM, YeoGW (2017) Systematic review of dementia prevalence and incidence in United States race/ethnic populations. Alzheimers Dement13, 72–83.
8.
ShadlenMF, LarsonEB, GibbonsL, McCormickWC, TeriL (1999) Alzheimer’s disease symptom severity in blacks and whites. J Am Geriatr Soc47, 482–486.
9.
LivneyMG, ClarkCM, KarlawishJH, CartmellS, NegronM, NunezJ, XieSX, Entenza-CabreraF, VegaIE, ArnoldSE (2011) Ethnoracial differences in the clinical characteristics of Alzheimer’s disease at initial presentation at an urban Alzheimer’s disease center. Am J Geriatr Psychiatry19, 430–439.
10.
CooperC, TandyAR, BalamuraliTB, LivingstonG (2010) A systematic review and meta-analysis of ethnic differences in use of dementia treatment, care, and research. Am J Geriatr Psychiatry18, 193–203.
11.
PotterGG, PlassmanBL, BurkeJR, KabetoMU, LangaKM, LlewellynDJ, RogersMA, SteffensDC (2009) Cognitive performance and informant reports in the diagnosis of cognitive impairment and dementia in African Americans and whites. Alzheimers Dement5, 445–453.
12.
GreenRC, CupplesLA, GoR, BenkeKS, EdekiT, GriffithPA, WilliamsM, HippsY, Graff-RadfordN, BachmanD, FarrerLA, GroupMS (2002) Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA287, 329–336.
13.
TangMX, SternY, MarderK, BellK, GurlandB, LantiguaR, AndrewsH, FengL, TyckoB, MayeuxR (1998) The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA279, 751–755.
14.
SattlerC, ToroP, SchonknechtP, SchroderJ (2012) Cognitive activity, education and socioeconomic status as preventive factors for mild cognitive impairment and Alzheimer’s disease. Psychiatry Res196, 90–95.
15.
ClarkPC, KutnerNG, GoldsteinFC, Peterson-HazenS, GarnerV, ZhangR, BowlesT (2005) Impediments to timely diagnosis of Alzheimer’s disease in African Americans. J Am Geriatr Soc53, 2012–2017.
KukullWA, MartinGM (1998) APOE polymorphisms and late-onset Alzheimer disease: The importance of ethnicity. JAMA279, 788–789.
18.
ShinJ, DoraiswamyPM (2016) Underrepresentation of African-Americans in Alzheimer’s trials: A call for affirmative action. Front Aging Neurosci8, 123.
19.
SandbergG, StewartW, SmialekJ, TroncosoJC (2001) The prevalence of the neuropathological lesions of Alzheimer’s disease is independent of race and gender. Neurobiol Aging22, 169–175.
20.
RiudavetsMA, RubioA, CoxC, RudowG, FowlerD, TroncosoJC (2006) The prevalence of Alzheimer neuropathologic lesions is similar in blacks and whites. J Neuropathol Exp Neurol65, 1143–1148.
21.
WilkinsCH, GrantEA, SchmittSE, McKeelDW, MorrisJC (2006) The neuropathology of Alzheimer disease in African American and white individuals. Arch Neurol63, 87–90.
22.
Graff-RadfordNR, BesserLM, CrookJE, KukullWA, DicksonDW (2016) Neuropathologic differences by race from the National Alzheimer’s Coordinating Center. Alzheimers Dement12, 669–677.
23.
ReitzC, MayeuxR (2014) Genetics of Alzheimer’s disease in Caribbean Hispanic and African American populations. Biol Psychiatry75, 534–541.
SteinerJ, BogertsB, SchroeterML, BernsteinHG (2011) S100B protein in neurodegenerative disorders. Clin Chem Lab Med49, 409–424.
26.
Van EldikLJ, GriffinWS (1994) S100 beta expression in Alzheimer’s disease: Relation to neuropathology in brain regions. Biochim Biophys Acta1223, 398–403.
27.
GourasGK, TsaiJ, NaslundJ, VincentB, EdgarM, CheclerF, GreenfieldJP, HaroutunianV, BuxbaumJD, XuH, GreengardP, RelkinNR (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol156, 15–20.
28.
VorobyevVA, AlhoK, MedvedevSV, PakhomovSV, RoudasMS, RutkovskayaJM, TervaniemiM, Van ZuijenTL, NaatanenR (2004) Linguistic processing in visual and modality-nonspecific brain areas: PET recordingsduring selective attention. Brain Res Cogn Brain Res20, 309–322.
29.
McDermottKB, PetersenSE, WatsonJM, OjemannJG (2003) A procedure for identifying regions preferentially activated by attention to semantic and phonological relations using functional magnetic resonance imaging. Neuropsychologia41, 293–303.
30.
BrownS, MartinezMJ, ParsonsLM (2006) Music and language side by side in the brain: A PET study of the generation of melodies and sentences. Eur J Neurosci23, 2791–2803.
31.
AmanzioM, TortaDM, SaccoK, CaudaF, D’AgataF, DucaS, LeottaD, PalermoS, GeminianiGC (2011) Unawareness of deficits in Alzheimer’s disease: Role of the cingulate cortex. Brain134, 1061–1076.
32.
HuangYC, YenPS, WuST, ChenJT, HungGU, KaoCH, ChenTY, HoFM (2015) Brain metabolism of less-educated patients with Alzheimer dementia studied by positron emission tomography. Medicine (Baltimore)94, e1252.
33.
Vasconcelos LdeG, JackowskiAP, OliveiraMO, FlorYM, SouzaAA, BuenoOF, BruckiSM (2014) The thickness of posterior cortical areas is related to executive dysfunction in Alzheimer’s disease. Clinics (Sao Paulo)69, 28–37.
WoodLB, WinslowAR, ProctorEA, McGuoneD, MordesDA, FroschMP, HymanBT, LauffenburgerDA, HaigisKM (2015) Identification of neurotoxic cytokines by profiling Alzheimer’s disease tissues and neuron culture viability screening. Sci Rep5, 16622.
36.
LeeS, TongM, HangS, DeochandC, de la MonteS (2013) CSF and brain indices of insulin resistance, oxidative stress and neuro-inflammation in early versus late Alzheimer’s disease. J Alzheimers Dis Parkinsonism3, 128.
37.
ChenA, OakleyAE, MonteiroM, TuomelaK, AllanLM, Mukaetova-LadinskaEB, O’BrienJT, KalariaRN (2016) Multiplex analyte assays to characterize different dementias: Brain inflammatory cytokines in poststroke and other dementias. Neurobiol Aging38, 56–67.
38.
ZetterbergH, BlennowK (2013) Cerebrospinal fluid biomarkers for Alzheimer’s disease: More to come?J Alzheimers Dis33(Suppl 1), S361–S369.
39.
NakagawaS, CuthillIC (2007) Effect size, confidence interval and statistical significance: A practical guide for biologists. Biol Rev Camb Philos Soc82, 591–605.
40.
CohenJ (1994) The earth is round (p < 0.05). Am Psychol49, 997–1003.
41.
MrakRE, ShengJG, GriffinWS (1996) Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer’s disease. J Neuropathol Exp Neurol55, 273–279.
42.
MaaroufCL, KokjohnTA, WalkerDG, WhitesideCM, KalbackWM, WhetzelA, SueLI, SerranoG, JacobsonSA, SabbaghMN, ReimanEM, BeachTG, RoherAE (2014) Biochemical assessment of precuneus and posterior cingulate gyrus in the context of brain aging and Alzheimer’s disease. PLoS One9, e105784.
43.
ShengJG, MrakRE, RovnaghiCR, KozlowskaE, Van EldikLJ, GriffinWS (1996) Human brain S100 beta and S100 beta mRNA expression increases with age: Pathogenic implications for Alzheimer’s disease. Neurobiol Aging17, 359–363.
GriffinWS, StanleyLC, LingC, WhiteL, MacLeodV, PerrotLJ, WhiteCL3rd, AraozC (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A86, 7611–7615.
46.
BusinaroR, LeoneS, FabriziC, SorciG, DonatoR, LauroGM, FumagalliL (2006) S100B protects LAN-5 neuroblastoma cells against Abeta amyloid-induced neurotoxicity via RAGE engagement at low doses but increases Abeta amyloid neurotoxicity at high doses. J Neurosci Res83, 897–906.
47.
LeclercE, SturchlerE, VetterSW (2010) The S100B/RAGE axis in Alzheimer’s disease. Cardiovasc Psychiatry Neurol2010, 539581.
48.
EdwardsMM, RobinsonSR (2006) TNF alpha affects the expression of GFAP and S100B: Implications for Alzheimer’s disease. J Neural Transm (Vienna)113, 1709–1715.
49.
de SouzaDF, LeiteMC, Quincozes-SantosA, NardinP, TortorelliLS, RigoMM, GottfriedC, LealRB, GoncalvesCA (2009) S100B secretion is stimulated by IL-1beta in glial cultures and hippocampal slices of rats: Likely involvement of MAPK pathway. J Neuroimmunol206, 52–57.
50.
PenaLA, BrecherCW, MarshakDR (1995) beta-Amyloid regulates gene expression of glial trophic substance S100 beta in C6 glioma and primary astrocyte cultures. Brain Res Mol Brain Res34, 118–126.
51.
ShengJG, MrakRE, GriffinWS (1994) S100 beta protein expression in Alzheimer disease: Potential role in the pathogenesis of neuritic plaques. J Neurosci Res39, 398–404.
52.
FestoffBW, SajjaRK, van DredenP, CuculloL (2016) HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer’s disease. J Neuroinflammation13, 194.
53.
CaiZ, LiuN, WangC, QinB, ZhouY, XiaoM, ChangL, YanLJ, ZhaoB (2016) Role of RAGE in Alzheimer’s disease. Cell Mol Neurobiol36, 483–495.
54.
BierhausA, HumpertPM, MorcosM, WendtT, ChavakisT, ArnoldB, SternDM, NawrothPP (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl)83, 876–886.
55.
ZongH, MaddenA, WardM, MooneyMH, ElliottCT, StittAW (2010) Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. J Biol Chem285, 23137–23146.
56.
EmanueleE, D’AngeloA, TomainoC, BinettiG, GhidoniR, PolitiP, BernardiL, MalettaR, BruniAC, GeroldiD (2005) Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol62, 1734–1736.
57.
HernanzA, De la FuenteM, NavarroM, FrankA (2007) Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer’s disease and mild cognitive impairment patients. Neuroimmunomodulation14, 163–167.
58.
LiangF, JiaJ, WangS, QinW, LiuG (2013) Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer’s disease. J Clin Neurosci20, 357–361.
59.
ZhuH, DingQ (2015) Lower expression level of two RAGE alternative splicing isoforms in Alzheimer’s disease. Neurosci Lett597, 66–70.
60.
NozakiI, WatanabeT, KawaguchiM, AkatsuH, TsuneyamaK, YamamotoY, OheK, YonekuraH, YamadaM, YamamotoH (2007) Reduced expression of endogenous secretory receptor for advanced glycation endproducts in hippocampal neurons of Alzheimer’s disease brains. Arch Histol Cytol70, 279–290.
61.
SchmidtAM (2015) Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory disease. Vascul Pharmacol72, 1–8.
62.
Kumar-SinghS, TheunsJ, Van BroeckB, PiriciD, VennekensK, CorsmitE, CrutsM, DermautB, WangR, Van BroeckhovenC (2006) Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat27, 686–695.
63.
JanelidzeS, HertzeJ, ZetterbergH, Landqvist WaldoM, SantilloA, BlennowK, HanssonO (2016) Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. Ann Clin Transl Neurol3, 12–20.
64.
PostupnaN, KeeneCD, CranePK, Gonzalez-CuyarLF, SonnenJA, HewittJ, RiceS, HowardK, MontineKS, LarsonEB, MontineTJ (2015) Cerebral cortical Abeta42 and PHF-tau in 325 consecutive brain autopsies stratified by diagnosis, location, and APOE. J Neuropathol Exp Neurol74, 100–109.
65.
BinderJR, DesaiRH, GravesWW, ConantLL (2009) Where is the semantic system? A critical review and meta-analysis of 120 functional neuroimaging studies. Cereb Cortex19, 2767–2796.
66.
GuY, RazlighiQR, ZahodneLB, JanickiSC, IchiseM, ManlyJJ, DevanandDP, BrickmanAM, SchupfN, MayeuxR, SternY (2015) Brain amyloid deposition and longitudinal cognitive decline in nondemented older subjects: Results from a multi-ethnic population. PLoS One10, e0123743.
67.
MezJ, CosentinoS, BrickmanAM, HueyED, MayeuxR (2013) Different demographic, genetic, and longitudinal traits in language versus memory Alzheimer’s subgroups. J Alzheimers Dis37, 137–146.
68.
FillenbaumGG, HuberM, TaussigIM (1997) Performance of elderly white and African American community residents on the abbreviated CERAD Boston Naming Test. J Clin Exp Neuropsychol19, 204–210.
69.
ChinAL, NegashS, XieS, ArnoldSE, HamiltonR (2012) Quality, and not just quantity, of education accounts for differences in psychometric performance between African Americans and White Non-Hispanics with Alzheimer’s disease. J Int Neuropsychol Soc18, 277–285.
70.
BoiseL, HintonL, RosenHJ, RuhlMC, DodgeH, MattekN, AlbertM, DennyA, GrillJD, HughesT, LinglerJH, MorhardtD, ParfittF, Peterson-HazanS, PopV, RoseT, ShahRC (2017) Willingness to be a brain donor: A survey of research volunteers from 4 racial/ethnic groups. Alzheimer Dis Assoc Disord31, 135–140.
71.
SchniedersT, DannerDD, McGuireC, ReynoldsF, AbnerE (2013) Incentives and barriers to research participation and brain donation among African Americans. Am J Alzheimers Dis Other Demen28, 485–490.
72.
BarnesLL, ShahRC, AggarwalNT, BennettDA, SchneiderJA (2012) The Minority Aging Research Study: Ongoing efforts to obtain brain donation in African Americans without dementia. Curr Alzheimer Res9, 734–745.
73.
HernandezS, McClendonMJ, ZhouXH, SachsM, LernerAJ (2010) Pharmacological treatment of Alzheimer’s disease: Effect of race and demographic variables. J Alzheimers Dis19, 665–672.
74.
MehtaKM, YinM, ResendezC, YaffeK (2005) Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease. Neurology65, 159–162.
